product
use
prophylaxi
treatment
bleed
haemophilia
von
willebrand
diseas
also
use
prophylaxi
treatment
bleed
patient
diseas
result
factor
viii
fviii
defici
key
constitu
haemat
human
von
willebrand
factor
vwf
coagul
factor
fviii
haemat
manufactur
process
design
purifi
concentr
desir
vwf
fviii
protein
inactivateremov
virus
may
potenti
present
start
materi
ie
plasma
pool
fraction
haemat
lyophil
product
reconstitut
water
inject
prior
administr
facilit
appropri
blood
coagul
patient
haemat
formerli
known
fviii
hs
hepat
safe
hs
licens
introduc
german
market
year
ago
product
process
includ
pasteur
step
inactiv
virus
pasteur
step
involv
stabil
product
intermedi
aqueou
solut
h
sinc
time
sever
viru
reduct
measur
implement
increas
safeti
margin
final
product
includ
stringent
select
donor
screen
donat
marker
genom
virus
seroposit
donat
discard
plasma
pool
fraction
recheck
presenc
virus
prior
stage
manufactur
process
variou
step
haemat
manufactur
process
inactiv
remov
remain
virus
confirm
care
plan
studi
use
virus
divers
physicochem
characterist
includ
envelop
virus
concept
product
line
european
guidelin
address
three
complementari
approach
control
potenti
viral
contamin
biolog
product
includ
select
test
sourc
plasma
absenc
virus
ii
test
abil
product
process
remov
inactiv
virus
iii
test
product
appropri
stage
product
contamin
virus
addit
impact
new
pathogen
includ
prion
caus
agent
variant
diseas
vcjd
may
enter
plasma
pool
fraction
present
risk
recipi
product
care
assess
viru
valid
prion
evalu
studi
perform
assess
effect
new
pathogen
remov
andor
inactiv
manufactur
process
main
procedur
aim
reduc
load
infecti
virus
eman
plasma
haemat
manufactur
process
outlin
fig
select
control
start
materi
major
factor
qualiti
assur
haemat
manufactur
process
care
choos
start
materi
potenti
load
hazard
virus
reduc
minut
amount
even
elimin
improv
ensur
safeti
start
plasma
achiev
collect
process
exampl
care
select
donor
centr
donor
plasma
either
collect
plasmapheresi
sourc
plasma
design
collect
centr
own
audit
csl
behr
inspect
relev
author
whole
blood
donat
recov
plasma
collect
transfus
servic
donor
requir
undergo
physic
examin
provid
answer
predefin
questionnair
time
donat
questionnair
use
identifi
donor
could
pose
risk
term
transmit
pathogen
reject
donat
defer
donor
either
temporarili
indefinit
depend
risk
sourc
plasma
donat
first
donat
applic
donor
first
time
donor
initi
quarantin
quarantin
lift
donor
success
pass
second
medic
histori
assess
second
donat
screen
shown
free
virus
measur
result
healthi
popul
donor
known
qualifi
donor
commit
donat
plasma
sourc
plasma
donor
reach
statu
qualifi
donor
process
manufactur
therefor
destroy
qualifi
donor
made
donat
period
month
consid
applic
donor
donat
screen
virus
use
current
approv
serolog
nucleic
acid
amplif
assay
haemat
licens
faktor
fviii
hs
sever
screen
assay
use
detect
viral
marker
antibodi
viral
antigen
establish
significantli
improv
assay
detect
antibodi
human
immunodefici
viru
hiv
introduc
sinc
sensit
assay
greatli
improv
hiv
screen
assay
current
licens
europ
highli
effect
identifi
donor
infect
group
screen
assay
current
licens
use
usa
highli
effect
detect
year
unsuccess
attempt
identifi
agent
respons
parenter
transmit
hepat
known
hepat
c
viru
hcv
cdna
clone
express
protein
allow
detect
antibodi
major
serum
specimen
identifi
screen
assay
use
detect
antibodi
hcv
base
c
clone
introduc
earli
follow
screen
confirm
assay
employ
recombin
viral
antigen
current
highli
sensit
assay
use
detect
donor
previous
infect
hcv
screen
assay
hepat
b
viru
hbv
infect
also
improv
earli
detect
system
util
agar
gel
diffus
oppos
current
detect
assay
assay
licens
europ
detect
limit
less
ng
hbsag
plasma
serum
whilst
assay
licens
use
usa
slightli
lower
compar
detect
limit
plasmawhol
blood
donat
use
product
product
must
screen
use
sensit
specif
valid
assay
assay
must
approv
screen
blood
donat
purpos
transfus
countri
donat
collect
plasmawhol
blood
donat
must
neg
hcv
test
viral
marker
antibodi
hcv
encod
antigen
exhibit
sensit
limit
tempor
depend
fig
known
diagnost
window
particularli
relev
test
base
antibodi
detect
techniqu
encompass
period
serolog
screen
donat
neg
despit
sampl
actual
contain
infecti
viru
diagnost
window
occur
time
laps
individu
infect
viru
bodi
abil
recogn
viru
subsequ
gener
enough
specif
cell
ie
time
seroconvert
therefor
plasma
donat
store
inventori
hold
address
inform
sourc
plasma
obtain
sever
time
per
month
donor
store
least
day
inventori
hold
process
occur
inventori
hold
period
inform
relat
donor
assess
regard
suitabl
store
plasma
import
inform
whether
seroconvers
detect
subsequ
donat
donor
seroconvers
occur
store
donat
donor
remov
inventori
hold
destroy
thu
prevent
potenti
viru
contamin
seroneg
donat
process
plasma
pool
fraction
inform
whole
blood
donor
reveal
viru
infect
recipi
compon
donat
would
also
result
destruct
donor
store
plasma
inform
also
includ
result
test
genom
materi
virus
furthermor
new
inform
suitabl
donor
gather
inventori
hold
period
risk
assess
perform
store
donat
may
destroy
base
assess
outcom
therefor
util
inventori
hold
donat
may
present
risk
identifi
elimin
product
process
fig
donat
applic
donor
store
quarantin
second
donat
confirm
health
donor
first
donat
subsequ
forward
inventori
hold
serolog
screen
donat
hepat
viru
hav
human
parvoviru
establish
virus
short
virem
phase
result
product
protect
neutral
antibodi
clear
viru
bodi
potenti
confer
protect
therefor
antibodi
screen
similar
hiv
hcv
would
appropri
particular
virus
discard
donat
would
deplet
immunoglobulin
prepar
clinic
relev
antibodi
improv
sensit
screen
assay
assay
base
detect
antigen
hbv
viral
nucleic
acid
discuss
employ
enabl
viru
detect
rather
host
respons
viru
approach
offer
anoth
clear
advantag
detect
assay
also
allow
diagnost
window
significantli
reduc
fig
qualiti
control
purpos
ie
product
product
minim
contamin
virus
screen
programm
util
nucleic
acid
amplif
techniqu
nat
form
sensit
polymeras
chain
reaction
pcr
design
industri
use
implement
csl
behr
natpcr
test
use
csl
behr
detect
hbv
hcv
nucleic
acid
sinc
hav
high
titr
sinc
natpcr
test
scheme
shorten
estim
diagnost
window
around
day
hbv
day
hcv
day
fig
therefor
donat
enter
manufactur
process
sensit
natpcr
assay
consequ
contain
either
virus
load
detect
limit
assay
strategi
creat
mini
pool
natpcr
test
implement
avoid
unnecessari
plasma
loss
would
caus
dispos
larg
plasma
pool
fraction
natpcr
reactiv
detect
plasma
collect
addit
sampl
obtain
use
prepar
sampl
mini
pool
specif
natpcr
test
enabl
mini
pool
detect
caus
donat
individu
discard
enabl
natpcr
plasma
pool
creat
fraction
accord
european
guidelin
must
demonstr
util
valid
natpcr
test
guidelin
relev
hcv
cpmp
guidelin
use
conjunct
european
director
qualiti
medicin
edqm
us
food
drug
administr
usfda
provid
guidanc
use
nat
detect
nucleic
acid
hcv
effect
natpcr
test
sourc
plasma
donat
collect
fraction
facil
marburg
germani
kankake
illinoi
usa
bern
switzerland
shown
tabl
natpcr
test
scheme
use
screen
hbv
hcv
hav
window
donat
posit
donat
discard
prevent
enter
plasma
pool
fraction
previou
donat
donor
store
inventori
hold
also
discard
fig
degre
viru
reduct
potenti
achiev
discard
donat
shown
tabl
data
show
natpcr
test
perform
csl
behr
signific
impact
reduct
viru
load
plasma
pool
fraction
consid
effect
viru
reduct
step
ensur
process
test
donat
discard
reactiv
donat
pool
plasma
perform
success
final
plasma
pool
fraction
test
absenc
viral
marker
hbsag
antibodi
genom
materi
hav
hbv
hcv
high
titr
base
regulatori
requir
csl
behr
voluntari
standard
plasma
pool
releas
process
test
result
show
pool
qualiti
control
measur
implement
csl
behr
hcv
detect
base
analyt
sensit
natpcr
assay
plasma
pool
releas
consider
lower
assay
sensit
requir
european
medicin
agenc
emea
hcv
although
regulatori
requir
implement
virus
csl
behr
releas
criteria
hav
hbv
set
similarli
low
assay
sensit
hcv
iu
plasma
pool
fraction
comparison
blood
transfus
releas
load
hcv
less
iu
per
ml
donat
plasma
implement
rigor
test
scheme
signific
reduct
viru
load
start
materi
haemat
product
achiev
preproduct
screen
process
facilit
viru
inactivationelimin
step
manufactur
procedur
viru
reduct
process
product
expos
limit
amount
virus
develop
pasteur
fviii
product
began
behringwerk
marburg
predecessor
compani
csl
behr
introduct
pasteur
process
base
upon
excel
viru
safeti
record
human
serum
albumin
product
manufactur
subsequ
cold
ethanol
precipit
step
modif
cohn
process
pasteur
process
involv
product
aqueou
solut
h
take
place
final
contain
contrast
albumin
fviii
therefor
suscept
damag
pasteur
step
pasteur
fviii
product
nevertheless
success
develop
follow
discoveri
proprietari
stabil
combin
sucros
glycin
stabil
ad
aqueou
solut
protect
fviii
partial
denatur
whilst
still
allow
effect
viru
inactiv
product
pasteur
fviii
product
earli
develop
main
goal
creat
product
would
transmit
virus
time
three
hepat
virus
discov
hcv
still
known
hepat
viru
nomenclatur
use
viru
recogn
caus
agent
hepat
also
known
distinct
hav
hbv
despit
fact
infecti
agent
unknown
neither
hbv
hcv
propag
cell
cultur
small
anim
model
exist
infect
assay
virus
narrow
host
rang
infecti
viru
detect
quantifi
either
human
chimpanze
serv
anim
model
hbv
hcv
infect
consequ
viru
inactiv
studi
includ
chimpanze
two
hbv
inactiv
studi
design
assess
effect
haemat
manufactur
process
reduc
load
infecti
viru
intermedi
plasma
fraction
intermedi
consist
partial
fraction
materi
still
need
manufactur
step
becom
final
haemat
product
haemat
intermedi
prepar
laboratori
scale
accord
manufactur
process
incorpor
pasteur
step
chimpanze
inocul
either
start
materi
intermedi
plasma
fraction
pasteur
final
haemat
product
studi
util
differ
batch
intermedi
reduct
hcv
also
evalu
use
similar
inactiv
studi
hcv
inactiv
studi
sampl
pasteur
test
detail
inform
relat
three
studi
demonstr
effect
haemat
manufactur
process
elimin
hbvhcv
provid
tabl
rang
human
pathogen
virus
includ
polioviru
vaccinia
viru
three
herp
virus
cytomegaloviru
viru
herp
simplex
viru
propag
cell
cultur
employ
first
viru
valid
studi
hiv
initi
known
htlv
iii
human
leukaemia
viru
iii
discov
also
studi
cell
cultur
consider
heat
sensit
demonstr
studi
date
employ
wide
rang
human
anim
pathogen
virus
assess
viru
inactiv
capac
pasteur
step
tabl
contain
exampl
virus
test
demonstr
effect
inactiv
pasteur
step
viru
inactiv
pasteur
verifi
viru
valid
studi
step
product
haemat
adsorpt
precipit
valid
abil
remov
virus
product
process
european
author
releas
first
guidelin
viru
valid
studi
biolog
product
deriv
either
cell
bank
human
anim
origin
blood
biolog
fluid
human
anim
tissu
guidelin
cover
design
implic
limit
valid
studi
includ
recommend
select
appropri
virus
use
viru
valid
studi
guidelin
sinc
updat
current
third
revis
viru
valid
studi
improv
confid
safeti
biolog
product
regard
potenti
viru
transmiss
identifi
product
step
effect
reduc
level
infecti
viru
contribut
reduct
infecti
viru
consequ
estim
overal
abil
manufactur
procedur
inactiv
andor
remov
contamin
infecti
virus
obtain
virus
chosen
valid
studi
possibl
close
resembl
virus
may
potenti
contamin
product
test
abil
product
process
remov
virus
gener
also
repres
wide
rang
properti
studi
strain
virus
replic
high
titr
cell
cultur
assay
effect
sensit
reliabl
vitro
infect
assay
chosen
csl
behr
routin
infect
assay
current
avail
hbv
hcv
although
research
infect
assay
establish
csl
behr
consequ
virus
use
viru
valid
studi
appropri
model
virus
use
instead
tabl
respect
haemat
manufactur
process
viru
valid
studi
perform
base
guidelin
emea
formerli
known
european
agenc
evalu
medicin
product
document
provid
gener
guidanc
viru
valid
studi
specif
guidanc
medicin
product
viru
valid
report
submit
author
licens
haemat
take
consider
overal
risk
transmit
virus
applic
product
recipi
formal
viru
valid
studi
haemat
employ
fix
panel
virus
includ
list
human
immunodefici
viru
employ
viru
valid
studi
relev
viru
propag
cell
cultur
system
addit
limit
studi
employ
perform
demonstr
equal
sensit
studi
regular
basi
respond
inactiv
procedur
similar
manner
bovin
viral
diarrhoea
viru
pestiviru
genu
famili
flavivirida
initi
introduc
panel
virus
employ
viru
valid
studi
close
relat
hcv
model
virus
either
flaviviru
genu
eg
enceph
viru
alphaviru
genu
famili
togavirida
eg
sindbi
viru
semliki
forest
viru
addit
west
nile
viru
wnv
flaviviru
genu
use
pasteur
studi
hepat
viru
use
valid
studi
thought
significantli
differ
picornavirus
recogn
viru
canin
parvoviru
cpv
select
viru
valid
studi
human
parvoviru
antibodi
may
present
plasma
pool
contrast
bovin
parvoviru
antibodi
cpv
use
model
viru
repres
small
virus
resist
treatment
select
relev
viru
demonstr
effect
inactiv
pasteur
process
pseudorabi
viru
porcin
herpesviru
select
model
viru
complex
structur
envelop
viru
dna
genom
manufactur
process
haemat
consist
sever
step
purifi
concentr
fviii
vwf
cryoprecipit
al
oh
adsorpt
glycin
precipit
nacl
precipit
dialysi
ultracentrifug
steril
filtrat
viru
valid
studi
select
step
stage
manufactur
process
employ
assess
effect
could
remov
rang
virus
experi
base
version
purif
process
valid
close
mimic
product
scale
manufactur
process
furthermor
viru
inactiv
capac
pasteur
valid
wide
rang
virus
studi
perform
deliber
ad
cell
cultur
deriv
stock
either
virus
appropri
select
model
virus
product
intermedi
deriv
actual
haemat
product
lot
amount
viru
infect
remov
inactiv
subsequ
stage
stage
manufactur
procedur
demonstr
viru
valid
studi
extent
viru
removalinactiv
individu
stage
combin
stage
product
process
test
least
twice
independ
result
viru
valid
studi
procedur
use
predict
effect
manufactur
process
inactiv
remov
virus
use
wide
rang
virus
valid
studi
also
provid
indirect
evid
product
process
could
effect
inactiv
remov
novel
unpredict
viral
contamin
addit
provid
accur
reflect
manufactur
procedur
version
product
process
also
use
robust
studi
robust
studi
evalu
product
paramet
may
influenc
viru
inactiv
andor
remov
includ
paramet
concentr
protein
compon
precipit
agent
temperatur
ph
reaction
time
amount
stabil
temperatur
pasteur
step
robust
studi
perform
laboratori
use
paramet
beyond
rang
specifi
routin
product
impact
extrem
product
paramet
effect
viru
reduct
step
assess
new
emerg
virus
may
novel
zoonot
virus
encount
human
enter
new
geograph
area
come
contact
previous
undiscov
anim
virus
cross
speci
barrier
enter
human
diseas
chain
hiv
yellow
fever
viru
sever
acut
respiratori
syndrom
coronaviru
menangl
viru
hendra
viru
nipah
viru
well
hantavirus
monkeypox
viru
furthermor
new
viru
new
geograph
region
wnv
known
africa
middl
east
emerg
north
america
new
virus
may
also
occur
de
novo
mutat
eg
influenza
virus
improv
diagnost
method
result
detect
previous
unknown
virus
consid
emerg
virus
rather
establish
agent
detect
describ
first
time
eg
first
detect
hcv
detect
human
herpesviru
type
discov
transfus
transmiss
viru
ttv
detect
note
virus
detect
first
time
improv
diagnost
method
may
virus
without
current
attribut
symptom
diseas
ttv
human
herp
viru
type
gb
viru
gb
viru
b
gb
viru
chepat
g
viru
even
virus
origin
detect
context
clinic
symptom
patient
csl
behr
dilig
assess
potenti
threat
emerg
diseas
regard
safeti
haemat
product
outlin
ludlam
et
al
newli
describ
agent
concern
regard
product
meet
challeng
haemat
potenti
epidemiolog
new
emerg
pathogen
donor
popul
potenti
load
infecti
virus
donat
symptomless
incub
period
address
emerg
virus
exclud
donor
popul
dilig
surveil
avail
inform
new
emerg
virus
may
result
tempor
deferr
donor
base
geograph
risk
complianc
regulatori
guidanc
eg
wnv
limit
data
avail
viru
load
potenti
emerg
virus
donor
popul
wnv
viru
load
asymptomat
donor
gener
less
infecti
unit
per
ml
blood
relev
titr
plasma
exclud
even
clinic
case
maximum
number
genom
copi
detect
preclin
situat
detect
viru
titr
order
genom
copi
per
ml
donor
may
donat
incub
period
provid
defer
base
geograph
andor
travel
histori
howev
potenti
viru
load
donat
particular
plasma
pool
fraction
would
low
thu
viru
reduc
capac
manufactur
process
would
effect
reduc
quantiti
emerg
virus
studi
assess
abil
pasteur
inactiv
wide
rang
virus
select
emerg
virus
relev
model
virus
employ
tabl
show
effect
viru
inactiv
capac
pasteur
rang
new
emerg
virus
demonstr
effect
reduct
infect
within
pasteur
process
till
abnorm
prion
protein
never
detect
blood
infect
human
even
detect
lymphoid
tissu
individu
transmiss
prion
never
report
plasma
medicin
product
contrast
probabl
transmiss
vcjd
four
case
transfus
red
blood
cell
concentr
unit
kingdom
patient
uk
resid
may
dietari
exposur
bse
howev
likelihood
infect
bse
consid
far
lower
transmiss
prion
blood
transfus
laboratori
studi
use
anim
shown
cellular
compon
blood
like
contain
pathogen
agent
vcjd
prpsc
splenic
lymphocyt
acquir
prion
possibl
follicular
dendrit
cell
implic
pathogenesi
vcjd
although
infect
appear
associ
circul
lymphocyt
link
leucocyt
infect
remain
controversi
consequ
effect
vcjd
transmiss
infect
donor
remain
uncertain
even
sinc
octob
leucocyt
remov
blood
use
transfus
unit
kingdom
plasma
use
fraction
product
haemat
alway
collect
method
plasmapheresi
plasma
process
recov
plasma
whole
blood
collect
addit
measur
implement
minim
theoret
risk
contamin
plasma
pool
human
tse
precaut
donor
may
potenti
present
risk
perman
exclud
donat
plasma
includ
donor
clinic
diagnosi
cjd
vcjd
donor
suspect
cjd
vcjd
increas
risk
develop
diseas
recipi
dura
mater
graft
substanc
deriv
human
pituitari
gland
eg
growth
hormon
gonadotropin
blood
rel
diagnos
cjd
deferr
recommend
includ
travel
resid
unit
kingdom
defin
period
time
accord
regulatori
guidanc
minim
theoret
risk
human
tse
contamin
plasma
pool
donor
may
present
risk
exclud
perman
donat
plasma
specifi
current
fda
guidanc
document
provid
guidanc
donat
collect
usa
similar
measur
implement
european
donor
protein
concentr
market
europ
whilst
csl
behr
qualiti
deliveri
requir
standard
contract
plasma
supplier
csl
behr
includ
even
stringent
measur
unpool
unit
plasma
donor
risk
develop
cjd
previous
unrecogn
increas
risk
acquir
cjd
accord
mention
criteria
interdict
exclud
manufactur
process
precautionari
measur
minim
theoret
risk
cjd
contamin
plasma
pool
unlik
event
donor
diagnos
vcjd
clinic
suspect
vcjd
subsequ
make
donat
plasma
process
finish
product
batch
affect
product
quarantin
withdrawn
market
close
cooper
respons
regulatori
author
precautionari
measur
csl
behr
use
plasma
uk
donor
uk
significantli
vcjd
case
countri
death
attribut
either
definit
probabl
case
vcjd
three
peopl
current
live
definiteprob
vcjd
januari
case
vcjd
franc
januari
reason
csl
behr
current
use
french
plasma
done
sinc
first
vcjd
case
report
franc
howev
plasma
french
donor
gener
accept
fraction
ratio
consid
favour
european
author
fda
guidelin
regul
concern
author
follow
wherev
plasma
collect
product
market
implement
precautionari
measur
low
risk
collect
plasma
donor
subsequ
develop
vcjd
addit
base
anim
studi
amount
prion
protein
present
plasma
donor
give
blood
whilst
incub
period
vcjd
consid
low
despit
low
risk
vcjd
transmiss
associ
plasma
abil
manufactur
process
step
elimin
prion
consid
prion
remov
studi
use
evalu
effect
select
step
haemat
manufactur
process
remov
prion
protein
prpsc
never
isol
human
blood
plasma
prion
protein
use
investig
studi
obtain
deliber
infect
laboratori
anim
primarili
includ
scrapi
agent
isol
hamster
brain
use
model
human
prion
knowledg
natur
potenti
prion
contamin
plasma
two
differ
prion
spike
prepar
employ
evalu
studi
name
microsom
prion
purifi
prpsc
associ
form
infecti
prion
protein
laboratori
studi
perform
spike
experiment
plasma
pool
intermedi
manufactur
process
prion
prepar
immunoassay
cdi
accord
safar
et
al
describ
use
quantifi
amount
prion
materi
present
prion
quantifi
spike
start
materi
final
sampl
insid
fraction
obtain
manufactur
process
determin
extent
prion
reduct
cdi
util
monoclon
antibodi
mab
recogn
epitop
present
form
prion
protein
prpc
prpsc
nativ
conform
infecti
isoform
epitop
recogn
mab
access
whilst
denatur
form
prpsc
well
nativ
denatur
form
prpc
normal
cellular
isoform
epitop
expos
fulli
access
immunoassay
record
amount
prion
protein
use
fluoresc
trf
valu
obtain
signal
sampl
test
parallel
nativ
form
well
denatur
form
prpsc
present
signal
compar
mab
detect
nativ
denatur
form
prpc
prpsc
present
signal
higher
denatur
sampl
mab
detect
denatur
form
prpsc
therefor
sampl
contain
prpsc
signal
denatur
sampl
divid
signal
sampl
denatur
result
ratio
greater
calcul
prion
remov
factor
given
manufactur
step
dilut
seri
construct
sampl
manufactur
intermedi
collect
manufactur
step
perform
use
start
materi
ratio
sampl
dilut
trf
denatur
sampl
trf
nativ
sampl
use
plot
curv
doubl
logarithm
diagram
fig
result
trend
line
measur
level
prion
remov
manufactur
step
distanc
trend
line
two
sampl
start
materi
final
sampl
manufactur
step
calcul
parallel
line
model
improv
version
cdi
known
sandwich
cdi
sinc
develop
sandwich
cdi
microtitr
plate
coat
captur
antibodi
techniqu
far
sensit
captur
antibodi
specif
enrich
prion
protein
bound
plate
whilst
direct
cdi
bind
prpsc
effici
minor
et
al
report
result
vitro
collabor
studi
demonstr
sensit
detect
prion
cdi
especi
sandwich
cdi
compar
publish
data
standard
cdi
approxim
sensit
sensit
western
blot
assay
sandwich
cdi
least
sensit
prion
evalu
studi
shown
variou
step
haemat
manufactur
process
studi
combin
highli
effect
remov
prion
protein
overal
reduct
prion
protein
manufactur
step
studi
prion
microsom
purifi
prpsc
tabl
addit
data
support
low
risk
prion
transmiss
haemat
result
spike
studi
involv
singl
manufactur
step
glycin
precipit
step
studi
employ
human
prion
prepar
sporad
cjd
vcjd
spike
materi
addit
scrapi
agent
furthermor
prion
reduct
capac
precipit
step
studi
use
scrapi
strain
hamster
bioassay
perform
feder
research
institut
infecti
diseas
anim
germani
reduct
prion
protein
microsom
purifi
prpsc
achiev
glycin
precipit
step
manufactur
process
compar
form
prion
prepar
regardless
differ
properti
measur
either
cdi
hamster
bioassay
tabl
consequ
detect
quantif
prion
protein
biochem
method
appropri
method
evalu
prion
reduct
factor
manufactur
process
protein
detect
human
prion
safar
et
al
demonstr
within
linear
rang
good
correl
prpsc
concentr
measur
sandwich
cdi
prion
titr
measur
titrat
bioassay
mice
indic
assay
compar
sensit
level
studi
lee
et
al
sever
plasma
protein
purif
step
test
spike
plasma
intermedi
infect
hamster
brain
homogen
evalu
prion
reduct
capac
use
either
western
blot
assay
hamster
bioassay
result
confirm
suitabl
use
biochem
method
detect
quantifi
prion
protein
western
blot
assay
prion
evalu
studi
anoth
set
experi
gregori
et
al
remov
prion
protein
cold
ethanol
precipit
step
studi
use
either
hamster
bioassay
detect
prion
protein
brain
homogen
hamster
western
blot
assay
detect
prpsc
fibril
compar
prion
reduct
factor
demonstr
prion
quantif
method
prion
protein
consid
agent
biochemicalserolog
method
prion
quantif
suffici
assess
prion
reduct
factor
assess
potenti
risk
prion
transmiss
haemat
potenti
quantiti
prion
protein
present
start
materi
remov
prion
manufactur
process
must
consid
epidemiolog
vcjd
indic
current
donor
uk
franc
may
pose
vcjd
risk
contrast
plasma
donat
european
countri
usa
base
donor
deferr
criteria
implement
csl
behr
assum
donat
one
potenti
infect
donor
would
enter
plasma
pool
suffici
size
produc
one
batch
haemat
addit
prion
load
donat
would
low
level
infect
blood
estim
approxim
two
per
ml
blood
one
probabl
caus
infect
administ
via
intraven
therapi
therefor
even
worst
case
scenario
prion
load
plasma
pool
fraction
consid
low
prion
potenti
present
plasma
pool
would
remov
effect
manufactur
process
overal
final
product
would
present
remot
risk
prion
transmiss
principl
requir
safe
product
met
overal
prion
reduct
factor
clearli
exce
potenti
prion
load
enter
manufactur
pool
lead
adequ
safeti
margin
finish
product
state
virus
european
regulatori
author
overal
prion
reduct
factor
least
clearli
exce
potenti
prion
load
therefor
risk
vcjd
transmiss
applic
haemat
extrem
remot
anoth
way
assess
risk
prion
transmiss
estim
potenti
infect
prion
per
vial
product
calcul
imagin
scenario
highest
possibl
prion
load
start
materi
multipli
prion
concentr
volum
plasma
requir
produc
one
vial
result
figur
divid
prion
reduct
factor
obtain
evalu
studi
base
worst
case
scenario
safeti
factor
calcul
meet
steril
assur
level
accord
pharmacopoeia
worldwid
demonstr
high
margin
safeti
haemat
respect
vcjd
transmiss
sever
variabl
even
unknown
associ
calcul
safeti
margin
eg
epidemiolog
vcjd
countri
csl
behr
collect
plasma
haemat
potenti
prion
load
plasma
donor
develop
vcjd
make
donat
incub
period
vcjd
assum
infecti
prion
present
blood
whole
incub
period
volum
donat
yield
vwffviii
result
probabl
model
appropri
calcul
safeti
margin
approach
use
fda
determin
prion
reduct
factor
least
would
result
fviii
product
remot
risk
vcjd
transmiss
consid
prion
reduct
factor
haemat
least
calcul
risk
vcjd
transmiss
use
approach
result
neglig
risk
transmiss
follow
administr
haemat
manufactur
area
procedur
util
haemat
product
segreg
prevent
product
adventiti
agent
appropri
materi
use
construct
product
facil
movement
personnel
product
intermedi
regul
manufactur
process
use
dedic
workforc
materi
airlock
appropri
requir
class
clean
room
exampl
air
exchang
rate
adequ
pressur
differenti
room
differ
classif
provid
appropri
heat
ventil
air
condit
system
addit
construct
product
facil
segreg
inactiv
inactiv
area
sever
studi
provid
assur
adventiti
agent
potenti
retain
product
system
would
adequ
destroy
equip
sanit
procedur
carri
prior
next
product
cycl
studi
demonstr
treatment
sodium
hydroxid
naoh
commerci
alkalin
clean
solut
effici
remov
andor
inactiv
virus
test
date
data
agre
unpublish
data
csl
behr
demonstr
virus
studi
inactiv
effect
even
room
temperatur
tabl
inactiv
remov
tse
sanit
clean
fraction
equip
also
evalu
tse
known
resist
varieti
physic
chemic
method
therefor
inactiv
infecti
prion
protein
particularli
difficult
achiev
certain
treatment
prove
reason
effect
includ
autoclav
soak
bleach
naoh
h
naoh
solut
commonli
use
clean
product
equip
treatment
also
convert
prpsc
form
result
inactiv
prion
tabl
csl
behr
file
convers
prion
protein
naoh
treatment
result
loss
infect
summari
product
equip
follow
sanit
period
use
appropri
concentr
naoh
commerci
alkalin
clean
solut
hiv
hcv
infect
patient
haemophilia
chang
made
approach
product
product
haemat
first
produc
manufactur
process
reli
heavili
pasteur
inactiv
infecti
virus
current
safeti
product
attribut
pasteur
manufactur
step
sever
addit
safeti
measur
design
minim
load
infecti
virus
either
plasma
pool
fraction
start
materi
haemat
product
current
process
see
fig
begin
collect
plasma
approv
collect
centr
suitabl
healthi
donor
donat
screen
hbsag
antibodi
hcv
sensit
screen
assay
markedli
increas
last
year
point
exampl
detect
rate
hbv
assay
reduc
least
ng
hbsag
per
ml
delay
antibodi
product
viral
infect
possibl
serolog
assay
gener
neg
result
despit
presenc
high
load
infecti
viru
viru
load
donat
reduc
low
level
natpcr
test
furthermor
posit
result
screen
plasma
donat
result
remov
previou
donat
held
inventori
hold
reduc
potenti
viru
load
plasma
pool
fraction
approach
highli
sensit
low
analyt
detect
limit
less
iu
differ
viru
genom
use
mini
pool
assay
donat
serolog
natpcr
test
pool
enter
manufactur
process
process
desir
protein
purifi
concentr
manufactur
step
also
contribut
toward
remov
virus
effect
scrutin
viru
valid
studi
product
intermedi
pasteur
inactiv
virus
may
potenti
present
effect
pasteur
process
inactiv
wide
rang
envelop
virus
thoroughli
document
experiment
evid
suggest
procedur
effect
remov
inactiv
wide
rang
virus
divers
characterist
includ
envelop
virus
although
virus
consid
resist
heat
pasteur
process
alon
account
viru
inactiv
factor
hav
concept
viru
safe
haemat
base
care
select
donor
centr
screen
donat
virus
subsequ
releas
plasma
pool
fraction
base
result
hav
hbv
hcv
high
titr
sensit
natpcr
assay
viru
reduct
capac
manufactur
process
haemat
viru
reduct
capac
haemat
manufactur
process
includ
especi
dedic
viru
inactiv
step
pasteur
manufactur
step
reliabl
contribut
overal
viru
reduct
approach
agreement
european
guidelin
second
step
requir
close
gap
first
step
certain
type
viru
exampl
addit
manufactur
step
requir
reduc
virus
product
treat
solventdeterg
new
emerg
virus
may
pose
risk
safeti
product
also
subject
pasteur
evalu
studi
studi
use
either
potenti
emerg
viru
relev
model
virus
confirm
pasteur
effect
inactiv
potenti
threat
tse
detect
natpcr
lack
nucleic
acid
remov
manufactur
process
haemat
current
prion
evalu
studi
success
shown
prion
reduct
factor
achiev
manufactur
process
clearli
surpass
potenti
prion
load
plasma
pool
conclus
viru
detect
measur
thorough
valid
process
paramet
viru
reduct
capac
improv
safeti
margin
product
continu
improv
pathogen
detect
techniqu
donat
qualiti
assur
system
pathogen
removalinactiv
procedur
togeth
surveil
new
transmiss
hazard
ensur
high
standard
safeti
continu
maintain
futur
author
employe
csl
behr
